The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer

Anticancer Res. 2020 Mar;40(3):1503-1512. doi: 10.21873/anticanres.14095.

Abstract

Aim: We examined whether the perioperative systemic inflammation score (SIS), which describes systemic inflammation and/or malnutrition, affected the tumor recurrence and survival in advanced gastric cancer patients.

Patients and methods: The study retrospectively analyzed 160 patients with stage II/III gastric cancer who underwent curative resection at the Kanagawa Cancer Center. The SIS was evaluated before surgery, one week after surgery and one month after surgery, as determined by the serum albumin level (cut-off value=4.0 g/dl) and lymphocyte-to-monocyte ratio (cut-off value=4.44).

Results: A high SIS at one month after surgery was identified as an independent predictor for overall survival [hazard ratio (HR)=2.143, p=0.020] and showed a marginal significance for the relapse-free survival (HR=1.814, p=0.053) in multivariate analyses.

Conclusion: The SIS at one month after surgery is a useful biomarker for predicting the long-term outcome in patients with advanced gastric cancer.

Keywords: Systemic inflammation score; gastrectomy; gastric cancer.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Capecitabine / administration & dosage
  • Chemotherapy, Adjuvant
  • Humans
  • Inflammation / blood
  • Inflammation / pathology*
  • Lymphocytes / pathology
  • Middle Aged
  • Monocytes / pathology
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Staging
  • Oxaloacetates / administration & dosage
  • Perioperative Period
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / blood
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / surgery
  • Survival Analysis
  • Young Adult

Substances

  • Oxaloacetates
  • Capecitabine

Supplementary concepts

  • XELOX